Article Details

GlaxoSmithKline agrees $2.2bn dementia mAb deal with Alector

Retrieved on: 2021-07-02 14:03:45

Tags for this article:

Click the tags to see associated articles and topics

GlaxoSmithKline agrees $2.2bn dementia mAb deal with Alector. View article details on hiswai:

Excerpt

The focus of the deal is two clinical-stage monoclonal antibodies – AL001 and AL101 – that are designed to bolster progranulin (PGRN) levels. PGRN ...

Article found on: www.pmlive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up